[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502254":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":23,"studyPopulation":23,"armGroups":34,"interventions":46,"overallOfficials":23,"centralContacts":23,"locations":54,"responsibleParty":251,"collaborators":23,"id":253,"slug":23,"hasResults":254,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":254,"sex":259,"minAge":260,"maxAge":23,"enrollmentInfo":261,"targetDuration":23,"studyType":264,"phases":265,"briefSummary":267,"conditions":268,"keywords":23,"overallStatus":57,"whyStopped":23,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},{"fullName":5,"class":6},"Minoryx Therapeutics, S.L.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":23},[9,12,14],{"measure":10,"description":10,"timeFrame":11},"The primary endpoint will be the time to death or the subject becoming bedridden with a requirement for permanent ventilatory support, wichever comes earlier, in subjects treated with leriglitazone compared to placebo.","Interim analysis 1 (at 18 months of treatment)",{"measure":10,"description":10,"timeFrame":13},"Interim analysis 2 (at 27 months of treatment)",{"measure":10,"description":10,"timeFrame":15},"Final analysis (at 36 months of treatment)",[17,20,22],{"measure":18,"description":19,"timeFrame":11},"Change from Baseline in Loes Score.","Change from Baseline in Loes Score. Loes Score Minimum = 0 Maximum =34 0 better outcome (healthy) 34 worst osutcome",{"measure":21,"description":19,"timeFrame":13},"Change from Baseline in Loes Score",{"measure":21,"description":19,"timeFrame":15},null,{"allocation":25,"interventionModel":26,"interventionModelDescription":23,"primaryPurpose":27,"observationalModel":23,"timePerspective":23,"maskingInfo":28},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":29,"maskingDescription":23,"whoMasked":30},"TRIPLE",[31,32,33],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[35,41],{"label":36,"type":37,"description":38,"interventionNames":39},"Leriglitazone","ACTIVE_COMPARATOR","Leriglitazone Treatment",[40],"Drug: Leriglitazone",{"label":42,"type":43,"description":42,"interventionNames":44},"Placebo","PLACEBO_COMPARATOR",[45],"Drug: Placebo",[47,51],{"type":48,"name":36,"description":49,"armGroupLabels":50,"otherNames":23},"DRUG","Leriglitazone at a strength of 15 mg\u002Fml. Once-daily dosing at an initial volume of 10 ml",[36],{"type":48,"name":42,"description":52,"armGroupLabels":53,"otherNames":23},"Placebo will match the study drug visually and by taste",[42],[55,75,86,101,116,131,141,156,171,187,203,219,235],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Stanford University Medical Center","RECRUITING","Palo Alto","California","94304-5978","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-122.14302,37.44188,{"lat":67,"lon":66},[70],{"name":71,"role":72,"phone":73,"phoneExt":23,"email":74},"Jacinda Sampson","CONTACT","650-723-0993","jacindas@stanford.edu",{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":61,"countryCode":62,"cosmosGeoPoint":81,"geoPoint":85,"contacts":23},"Neuro Medicine Hospital \u002F UF Health","WITHDRAWN","Gainesville","Florida","32608",{"type":64,"coordinates":82},[83,84],-82.32483,29.65163,{"lat":84,"lon":83},{"facility":87,"status":57,"city":88,"state":89,"zip":90,"country":61,"countryCode":62,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Kennedy Krieger Institute","Baltimore","Maryland","21205",{"type":64,"coordinates":92},[93,94],-76.61219,39.29038,{"lat":94,"lon":93},[97],{"name":98,"role":72,"phone":99,"phoneExt":23,"email":100},"Eric Mallack","443-923-2750","Mallack@kennedykrieger.org",{"facility":102,"status":57,"city":103,"state":104,"zip":105,"country":61,"countryCode":62,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":64,"coordinates":107},[108,109],-71.05977,42.35843,{"lat":109,"lon":108},[112],{"name":113,"role":72,"phone":114,"phoneExt":23,"email":115},"Reza Seyedsadjadi","617-726-5175","rseyedsadjadi@mgh.harvard.edu",{"facility":117,"status":57,"city":118,"state":119,"zip":120,"country":61,"countryCode":62,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"University of Minnesota","Minneota","Minnesota","55455",{"type":64,"coordinates":122},[123,124],-95.98559,44.55885,{"lat":124,"lon":123},[127],{"name":128,"role":72,"phone":129,"phoneExt":23,"email":130},"Troy Lund","612-625-4185","lundx072@umn.edu",{"facility":132,"status":77,"city":133,"state":134,"zip":135,"country":61,"countryCode":62,"cosmosGeoPoint":136,"geoPoint":140,"contacts":23},"Health University of Utah","Salt Lake City","Utah","84112",{"type":64,"coordinates":137},[138,139],-111.89105,40.76078,{"lat":139,"lon":138},{"facility":142,"status":57,"city":143,"state":23,"zip":23,"country":144,"countryCode":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Hospital Austral","Buenos Aires","Argentina","AR",{"type":64,"coordinates":147},[148,149],-58.37723,-34.61315,{"lat":149,"lon":148},[152],{"name":153,"role":72,"phone":154,"phoneExt":23,"email":155},"Hernan Amartino","+542304387458","carolina.acevedo@resolutioncrs.com",{"facility":157,"status":57,"city":158,"state":23,"zip":23,"country":159,"countryCode":160,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Federal University of Sao Paulo","São Paulo","Brazil","BR",{"type":64,"coordinates":162},[163,164],-46.63611,-23.5475,{"lat":164,"lon":163},[167],{"name":168,"role":72,"phone":169,"phoneExt":23,"email":170},"Paulo Sgobbi","+55(11)913323742","pvsgobbi@gmail.com",{"facility":172,"status":57,"city":173,"state":23,"zip":174,"country":175,"countryCode":176,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"ICM La Pitie Salpetriere","Paris","75013","France","FR",{"type":64,"coordinates":178},[179,180],2.3488,48.85341,{"lat":180,"lon":179},[183],{"name":184,"role":72,"phone":185,"phoneExt":23,"email":186},"Fanny Mochel","+ 33 (0)1 57 27 41 23","fanny.mochel@icm-institute.org",{"facility":188,"status":57,"city":189,"state":23,"zip":190,"country":191,"countryCode":192,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Klinik und Poliklinik für Neurologie-Leipzig","Leipzig","04103","Germany","DE",{"type":64,"coordinates":194},[195,196],12.37129,51.33962,{"lat":196,"lon":195},[199],{"name":200,"role":72,"phone":201,"phoneExt":23,"email":202},"Caroline Bergner","+49 341 97 11747","Caroline.Bergner@medizin.uni-leipzig.de",{"facility":204,"status":57,"city":205,"state":23,"zip":206,"country":207,"countryCode":208,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Sir Ganga Ram Hospital","New Delhi","110060","India","IN",{"type":64,"coordinates":210},[211,212],77.2148,28.62137,{"lat":212,"lon":211},[215],{"name":216,"role":72,"phone":217,"phoneExt":23,"email":218},"C.S Agrawal","+91 11 4225 1099","csyvaa@gmail.com",{"facility":220,"status":57,"city":221,"state":23,"zip":222,"country":223,"countryCode":224,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Hospital 12 de Octubre","Madrid","28041","Spain","ES",{"type":64,"coordinates":226},[227,228],-3.70256,40.4165,{"lat":228,"lon":227},[231],{"name":232,"role":72,"phone":233,"phoneExt":23,"email":234},"Montserrat Morales","630 742 050","montserrat.morales@salud.madrid.org",{"facility":236,"status":57,"city":237,"state":23,"zip":238,"country":239,"countryCode":240,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"National Hospital for Neurology and Neurosurgery","London","WC1N 3AX","United Kingdom","UK",{"type":64,"coordinates":242},[243,244],-0.12574,51.50853,{"lat":244,"lon":243},[247],{"name":248,"role":72,"phone":249,"phoneExt":23,"email":250},"Robin Lachman","+442034484778","r.lachmann@nhs.net",{"type":252,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100502254",false,"NCT05819866","A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy","CALYX","Key Inclusion Criteria:\n\n* Subject is male and aged ≥18 years.\n* Subject has progressive cALD, defined as GdE+ brain lesions.\n* Subjects for whom HSCT is not recommended by the investigator or subject is not willing to undergo HSCT.\n* Subject has a Loes score ≥0.5 and ≤12 at Screening.\n* Subject does not have major functional disability in the Major Functional Disabilities-Neurological Function Score (MFD-NFS), except for \"wheelchair bound\" or \"total incontinence\", which will be allowed as these are considered expected symptoms of AMN in the time course of the disease\n* Subject does not have major cognitive impairment which would impair his ability to take part in the study as determined by the investigator at screening.\n\nKey Exclusion Criteria:\n\n* Subject who had previous bone marrow transplantation (HSCT) or treatment with ex-vivo gene therapy (eli-Cel).\n* Subject has known type 1 or type 2 diabetes.\n* Subject has known hypersensitivity or intolerance to pioglitazone or any other thiazolidinedione.\n* Subject is taking or has taken honokiol, pioglitazone, or other thiazolidinediones within 3 months prior to Screening.\n* Subject with current participation in another interventional clinical study or within 1 month prior to Screening.\n* Subject with other medical, neuropsychiatric or social conditions that, in the opinion of the investigator, are likely to adversely affect the risk-benefit of study participation, interfere with study compliance, or confound the study results.","MALE","18 Years",{"count":262,"type":263},40,"ESTIMATED","INTERVENTIONAL",[266],"PHASE3","A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.",[269],"Cerebral Adrenoleukodystrophy (cALD)","2025-11-14",{"date":272,"type":273},"2025-11-17","ACTUAL",{"date":275,"type":273},"2023-07-12",{"date":277,"type":263},"2027-05",{"name":5,"class":6},13]